Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared an article by Boyu Leng, et al. on X:
“We also consider SBRT for oligoprogression in HCC b/c:
- high local control.
- usually low toxicity.
- allows pt to stay on 1st line chemo controlling non-progressive tumors.
- saves 2nd line in case of future more widespread disease.
This is a nice paper lending support to that strategy.”
Maintaining first-line therapy plus radiotherapy may prolong progression-free survival and delay second-line therapy for oligoprogressive hepatocellular carcinoma.
Authors: Boyu Leng, et al.
